Beam Therapeutics
Cambridge · Founded 2017
About Beam Therapeutics
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Total funding: $1.3B
- Funding stage: IPO
- Last round: Post-IPO Debt (Feb 2026)
- Ticker: nasdaq:BEAM
- Website: https://beamtx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/beam-therapeutics-69517 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.